ABK Biomedical Raises $35 Million in Series D Funding Led by J.P. Morgan Life Sciences
ABK Biomedical has secured $35 million in an oversubscribed Series D funding round led by J.P. Morgan Life Sciences Private Capital, with participation from existing investors. The funds will support clinical operations, commercialization of Eye90 microspheres, and expansion of manufacturing capabilities.